ABSTRACT
Background: The reduction in SARS-CoV-2 transmission facilitated by mobile contact tracing applications (apps) depends both on the proportion of relevant contacts notified and on the probability that those contacts quarantine after notification. The proportion of relevant contacts notified depends upon the number of days preceding an infector's positive test that their contacts are notified, which we refer to as an app's notification window. Methods: We use an epidemiological model of SARS-CoV-2 transmission that captures the profile of infection to consider the trade-off between notification window length and active app use. We focus on 5-day and 2-day windows, the notification windows of the NHS COVID-19 app in England and Wales before and after 2nd August 2021, respectively. Results: Our analyses show that at the same level of active app use, 5-day windows result in larger reductions in transmission than 2-day windows. However, short notification windows can be more effective at reducing transmission if they are associated with higher levels of active app use and adherence to isolation upon notification. Conclusions: Our results demonstrate the importance of understanding adherence to interventions when setting notification windows for COVID-19 contact tracing apps.
After submitting a positive SARS-CoV-2 test result, mobile contact-tracing apps identify 'recent' high-risk encounters with other app users, who are then notified of potential exposure. An app's success at limiting further transmission depends on the proportion of infected contacts notified. This depends on what counts as 'recent', e.g. notifying contacts from 5 days prior to the positive test can capture more infections than notifying contacts from 2 days prior. We call this number of days an app's notification window. However, an app's effectiveness also depends on whether or not exposed contacts use the app and adhere to isolation if notified. If shorter windows are associated with higher levels of active app use, they can be more effective at reducing transmission than longer windows, demonstrating the importance of considering the potential impact on active app use when setting an app's notification window length.
ABSTRACT
In nature, the interaction between pathogens and their hosts is only one of a handful of interaction relationships between species, including parasitism, predation, competition, symbiosis, commensalism, and among others. From a non-anthropocentric view, parasitism has relatively fewer essential differences from the other relationships;but from an anthropocentric view, parasitism and predation against humans and their well-beings and belongings are frequently related to heinous diseases. Specifically, treating (managing) diseases of humans, crops and forests, pets, livestock, and wildlife constitute the so-termed medical enterprises (sciences and technologies) humans endeavor in biomedicine and clinical medicine, veterinary, plant protection, and wildlife conservation. In recent years, the significance of ecological science to medicines has received rising attentions, and the emergence and pandemic of COVID-19 appear accelerating the trend. The facts that diseases are simply one of the fundamental ecological relationships in nature, and the study of the relationships between species and their environment is a core mission of ecology highlight the critical importance of ecological science. Nevertheless, current studies on the ecology of medical enterprises are highly fragmented. Here, we (i) conceptually overview the fields of disease ecology of wildlife, cancer ecology and evolution, medical ecology of human microbiome-associated diseases and infectious diseases, and integrated pest management of crops and forests, across major medical enterprises. (ii) Explore the necessity and feasibility for a unified medical ecology that spans biomedicine, clinical medicine, veterinary, crop (forest and wildlife) protection, and biodiversity conservation. (iii) Suggest that a unified medical ecology of human diseases is both necessary and feasible, but laissez-faire terminologies in other human medical enterprises may be preferred. (iv) Suggest that the evo-eco paradigm for cancer research can play a similar role of evo-devo in evolutionary developmental biology. (v) Summarized 40 key ecological principles/theories in current disease-, cancer-, and medical-ecology literatures. (vi) Identified key cross-disciplinary discovery fields for medical/disease ecology in coming decade including bioinformatics and computational ecology, single cell ecology, theoretical ecology, complexity science, and the integrated studies of ecology and evolution. Finally, deep understanding of medical ecology is of obvious importance for the safety of human beings and perhaps for all living things on the planet. Copyright © 2022 Ma and Zhang.
ABSTRACT
Background: The infection fatality ratio (IFR) is a key statistic for estimating the burden of coronavirus disease 2019 (COVID-19) and has been continuously debated throughout the COVID-19 pandemic. The age-specific IFR can be quantified using antibody surveys to estimate total infections, but requires consideration of delay-distributions from time from infection to seroconversion, time to death, and time to seroreversion (i.e. antibody waning) alongside serologic test sensitivity and specificity. Previous IFR estimates have not fully propagated uncertainty or accounted for these potential biases, particularly seroreversion. Methods: We built a Bayesian statistical model that incorporates these factors and applied this model to simulated data and 10 serologic studies from different countries. Results: We demonstrate that seroreversion becomes a crucial factor as time accrues but is less important during first-wave, short-term dynamics. We additionally show that disaggregating surveys by regions with higher versus lower disease burden can inform serologic test specificity estimates. The overall IFR in each setting was estimated at 0.49-2.53%. Conclusion: We developed a robust statistical framework to account for full uncertainties in the parameters determining IFR. We provide code for others to apply these methods to further datasets and future epidemics.
ABSTRACT
BACKGROUND: Persistence of antibodies to SARS-CoV-2 viral infection may depend on several factors and may be related to the severity of disease or to the different symptoms. METHODS: We evaluated the antibody response to SARS-CoV-2 in personnel from 9 healthcare facilities and an international medical school and its association with individuals' characteristics and COVID-19 symptoms in an observational cohort study. We enrolled 4735 subjects (corresponding to 80% of all personnel) for three time points over a period of 8-10 months. For each participant, we determined the rate of antibody increase or decrease over time in relation to 93 features analyzed in univariate and multivariate analyses through a machine learning approach. RESULTS: Here we show in individuals positive for IgG (≥12 AU/mL) at the beginning of the study an increase [p = 0.0002] in antibody response in paucisymptomatic or symptomatic subjects, particularly with loss of taste or smell (anosmia/dysgeusia: OR 2.75, 95% CI 1.753 - 4.301), in a multivariate logistic regression analysis in the first three months. The antibody response persists for at least 8-10 months. CONCLUSIONS: SARS-CoV-2 infection induces a long lasting antibody response that increases in the first months, particularly in individuals with anosmia/dysgeusia. This may be linked to the lingering of SARS-CoV-2 in the olfactory bulb.
ABSTRACT
Computational biology and bioinformatics resources provide a cutting-edge platform for the screening and development of novel therapeutic agents against probable targets of emerging viral diseases. Emerging viral infections such as COVID-19, Ebola, Nipha andMiddle East respiratory syndrome are some of the potential public health threats reported with high mortality and morbidity. The infections caused by these viruses were recently considered as acute onset immune dysrhythmia syndrome. The altered monocytic, cytokines and chemokines balances observed in several emerging viral infections lead to the acute respiratory distress and multiinflammatory syndromes [1]. Recent studies suggested that many countries were unable to manage the drastic and unexpected onset of these viral outbreaks and such a scenario adversely affected the global economy [2]. There are limited vaccines currently available for most of these viral infections and the vaccine development strategies are extremely tedious and complex. In addition, there are no approved drugs available for most of the emerging viral infections. For example, although the use of non toxic concentrations of 2-deoxy-D-glucose (2-DG), a glucose analog that inhibits the activity of phosphoglucoisomerase in the glycolytic pathway of SARS-CoV-2 is suggested to be one of the promising therapeutic agents for COVID-19, the successful application of this drug is yet to be confirmed [3]. Thus, the present editorial briefly outlines the scope of bioinformatics and computational biology toward the discovery of potential therapeutic agents against various viral diseases.